Amylyx Pharmaceuticals
AMLX
169 hedge funds and large institutions have $1.49B invested in Amylyx Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 57 funds opening new positions, 44 increasing their positions, 48 reducing their positions, and 19 closing their positions.
240% more call options, than puts
Call options by funds: $7.31M | Put options by funds: $2.15M
200% more first-time investments, than exits
New positions opened: 57 | Existing positions closed: 19
185% more capital invested
Capital invested by funds: $524M → $1.49B (+$967M)
50% more funds holding in top 10
Funds holding in top 10: 6 → 9 (+3)
31.41% more ownership
Funds ownership: 91.64% → 123.05% (+31%)
29% more funds holding
Funds holding: 131 → 169 (+38)
8% less repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 48
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$78.4M |
| 2 |
CC
Commodore Capital
New York
|
+$38.4M |
| 3 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$31.6M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$23.9M |
| 5 |
PBA
Paradigm Biocapital Advisors
New York
|
+$17.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$18.8M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$18.7M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$16.4M |
| 4 |
Millennium Management
New York
|
-$10.3M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$9.49M |
AMLX Hedge Fund Activity: Q3 2025 in Review
169 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Amylyx Pharmaceuticals (AMLX) for Q3 2025, worth a combined $1.49B — up 185% from $524M a quarter earlier.
Buyers outnumbered sellers: 57 funds opened new AMLX positions and 19 closed out — a net gain of 38 holders — while 44 added to existing stakes and 48 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $78.4M. The largest seller was Nantahala Capital Management, cutting an estimated $18.8M.
- 169 institutional investors held Amylyx Pharmaceuticals (AMLX) as of Q3 2025, up from 131 in Q2 2025.
- Funds reported $1.49B of Amylyx Pharmaceuticals stock for Q3 2025, up 185% quarter-over-quarter.
- 57 funds opened new Amylyx Pharmaceuticals positions in Q3 2025 and 19 closed out, a net change of +38 holders.
- The largest Amylyx Pharmaceuticals buyer in Q3 2025 was Fidelity Investments, an estimated $78.4M added.
- The largest Amylyx Pharmaceuticals seller in Q3 2025 was Nantahala Capital Management, an estimated $18.8M sold.
Based on aggregated 13F filings for Q3 2025.